Sorrento Therapeutics (SRNE) Competitors $0.0040 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesOptions ChainSEC FilingsSustainabilityTrends SRNE vs. NSTG, ERNA, CDIO, ORGS, BCDA, SHPH, JAGX, BMRA, HOTH, and EGRXShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include NanoString Technologies (NSTG), Eterna Therapeutics (ERNA), Cardio Diagnostics (CDIO), Orgenesis (ORGS), BioCardia (BCDA), Shuttle Pharmaceuticals (SHPH), Jaguar Health (JAGX), Biomerica (BMRA), Hoth Therapeutics (HOTH), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "medical" sector. Sorrento Therapeutics vs. NanoString Technologies Eterna Therapeutics Cardio Diagnostics Orgenesis BioCardia Shuttle Pharmaceuticals Jaguar Health Biomerica Hoth Therapeutics Eagle Pharmaceuticals NanoString Technologies (NASDAQ:NSTG) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Does the media refer more to NSTG or SRNE? In the previous week, NanoString Technologies' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score. Company Overall Sentiment NanoString Technologies Neutral Sorrento Therapeutics Neutral Which has stronger earnings and valuation, NSTG or SRNE? NanoString Technologies has higher revenue and earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanoString Technologies$127.26M0.00-$159.54M-$3.53N/ASorrento Therapeutics$60.32M0.04-$572.84MN/AN/A Which has more volatility and risk, NSTG or SRNE? NanoString Technologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Is NSTG or SRNE more profitable? Sorrento Therapeutics has a net margin of 0.00% compared to NanoString Technologies' net margin of -102.44%. Sorrento Therapeutics' return on equity of 0.00% beat NanoString Technologies' return on equity.Company Net Margins Return on Equity Return on Assets NanoString Technologies-102.44% -548.25% -53.79% Sorrento Therapeutics N/A N/A N/A Do analysts rate NSTG or SRNE? Given NanoString Technologies' higher possible upside, equities analysts plainly believe NanoString Technologies is more favorable than Sorrento Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoString Technologies 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Do insiders & institutionals believe in NSTG or SRNE? 0.0% of Sorrento Therapeutics shares are held by institutional investors. 3.1% of NanoString Technologies shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer NSTG or SRNE? Sorrento Therapeutics received 106 more outperform votes than NanoString Technologies when rated by MarketBeat users. Likewise, 69.24% of users gave Sorrento Therapeutics an outperform vote while only 61.61% of users gave NanoString Technologies an outperform vote. CompanyUnderperformOutperformNanoString TechnologiesOutperform Votes50461.61% Underperform Votes31438.39% Sorrento TherapeuticsOutperform Votes61069.24% Underperform Votes27130.76% SummarySorrento Therapeutics beats NanoString Technologies on 7 of the 11 factors compared between the two stocks. Ad Brownstone ResearchBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.21M$3.11B$5.02B$8.43BDividend YieldN/A1.76%7.52%4.16%P/E RatioN/A15.53128.7716.66Price / Sales0.04311.931,724.9679.31Price / CashN/A144.3536.9133.53Price / Book-0.083.994.605.19Net Income-$572.84M-$42.08M$114.09M$223.67M7 Day PerformanceN/A-0.30%110.41%2.70%1 Month PerformanceN/A9.28%124.29%8.76%1 Year PerformanceN/A29.07%154.67%28.76% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento TherapeuticsN/A$0.00flatN/A-94.6%$2.21M$60.32M0.00800Gap UpNSTGNanoString TechnologiesN/AN/AN/AN/A$5.07M$127.26M-0.03550Analyst ForecastGap DownERNAEterna Therapeutics0.234 of 5 stars$1.10+7.8%N/A-20.6%$5.95M$70,000.00-0.2510Upcoming EarningsCDIOCardio Diagnostics3.0907 of 5 stars$0.26-16.2%$2.00+671.6%-30.6%$5.88M$39,138.000.007Upcoming EarningsGap DownHigh Trading VolumeORGSOrgenesis2.7306 of 5 stars$1.17-4.9%N/AN/A$5.62M$530,000.000.00150Upcoming EarningsNews CoverageGap UpBCDABioCardia2.5744 of 5 stars$2.42-8.0%$25.00+933.1%-60.2%$5.59M$428,000.00-0.4516Gap UpSHPHShuttle Pharmaceuticals1.3318 of 5 stars$1.80+35.3%N/AN/A$5.31MN/A-0.525Upcoming EarningsGap DownHigh Trading VolumeJAGXJaguar Health0.7706 of 5 stars$1.08-4.4%N/A-94.5%$5.30M$10.19M0.0050Positive NewsBMRABiomerica0.9044 of 5 stars$0.31flatN/A-56.7%$5.23M$5.51M-0.8660Positive NewsGap DownHOTHHoth Therapeutics3.2869 of 5 stars$0.98+11.4%$3.50+258.8%-31.2%$5.23MN/A-0.614Upcoming EarningsAnalyst ForecastGap UpHigh Trading VolumeEGRXEagle Pharmaceuticals2.0603 of 5 stars$0.40+14.3%N/A-96.2%$5.20M$257.55M0.34134 Related Companies and Tools Related Companies NanoString Technologies Competitors Eterna Therapeutics Competitors Cardio Diagnostics Competitors Orgenesis Competitors BioCardia Competitors Shuttle Pharmaceuticals Competitors Jaguar Health Competitors Biomerica Competitors Hoth Therapeutics Competitors Eagle Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SRNE) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
